Skip to main content
Signal8

ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

ZyVersa Therapeutics, Inc. logo

ZyVersa Therapeutics, Inc.

OTC:ZVSAHealthcare
$0.0001
Mkt Cap$810
EV-
Float8.09M
O/S8.1M
VOL100 sh
$ Vol$0
RVOL0.07×
Inst Own0.0%
SI1.7%
Net Cash/Sh-
Dilution
  • AI analysis ›